Michael Benkowitz Sells 22,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $473.66, for a total value of $10,657,350.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Michael Benkowitz also recently made the following trade(s):

• On Monday, November 17th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $470.43, for a total value of $10,584,675.00.
• On Monday, November 10th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $452.07, for a total value of $10,171,575.00.
• On Monday, November 3rd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $429.25, for a total value of $9,658,125.00.
• On Monday, October 27th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $417.50, for a total value of $9,393,750.00.
• On Monday, October 20th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $427.41, for a total value of $9,616,725.00.
• On Monday, October 13th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $440.35, for a total transaction of $9,907,875.00.
• On Monday, October 6th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $450.24, for a total transaction of $10,130,400.00.
• On Monday, September 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $421.80, for a total transaction of $9,490,500.00.
• On Monday, September 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $416.35, for a total transaction of $9,367,875.00.
• On Monday, September 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $400.56, for a total transaction of $9,012,600.00.

United Therapeutics Stock Up 0.5%

Shares of UTHR stock opened at $488.43 on Friday. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $492.62. The firm has a fifty day moving average of $446.28 and a 200-day moving average of $360.53. The firm has a market capitalization of $21.03 billion, a price-to-earnings ratio of 18.51, a price-to-earnings-growth ratio of 4.96 and a beta of 0.77.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same period in the previous year, the company posted $6.39 earnings per share. The company’s revenue for the quarter was up 6.8% on a year-over-year basis. Research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Jefferies Financial Group reiterated a “buy” rating and set a $575.00 price objective on shares of United Therapeutics in a report on Wednesday, November 19th. HC Wainwright lifted their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Weiss Ratings reissued a “buy (b-)” rating on shares of United Therapeutics in a research report on Tuesday. Bank of America raised their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a report on Tuesday, September 2nd. Finally, Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research note on Wednesday, October 29th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $505.00.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Chung Wu Investment Group LLC bought a new position in United Therapeutics in the second quarter valued at approximately $29,000. WealthCollab LLC boosted its holdings in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its holdings in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares during the last quarter. SVB Wealth LLC bought a new position in shares of United Therapeutics in the first quarter valued at $32,000. Finally, Wilmington Savings Fund Society FSB increased its holdings in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.